Newsroom

Press Releases


Thermo Fisher Scientific to further expand global network of single-use technology manufacturing sites

Nashville site will deliver on strategy to enable reliable supply of critical materials used to produce new biologics and vaccines



WALTHAM, Mass., Sept. 8, 2021 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced plans to establish a manufacturing facility in Nashville dedicated to the production of single-use technologies (SUT) products. This investment is in addition to the previously announced expansion to address unprecedented demand in the bioprocessing market.  The facility will be one of the world's largest SUT manufacturing sites and will more than double the company's SUT manufacturing capacity in support of its biopharma customers. The first phase of construction will be operational by the second quarter of 2022.

"Over the last few years, more and more biological drugs and vaccines are being manufactured utilizing the single use platform. This has created incredible demand for our SUT products," said Michel Lagarde, executive vice president of Thermo Fisher Scientific. "The site in Nashville will be critical in Thermo Fisher's global network to continue to support the biopharma industry's work in developing life-saving biologics and vaccines." 

 

The Nashville site is part of Thermo Fisher's now more than $650 million capital investment to expand its bioprocessing production capabilities across 11 manufacturing sites in North America, Europe and Asia. Additional capacity will be added in 2021 with the completion of expansion projects in Logan, Utah, Suzhou, China, and a new SUT manufacturing site in Singapore. This additional capacity in the SUT network supports global customers as the company's manufacturing strategy utilizes equivalent processes and procedures to manufacture SUT products of consistent quality, form, fit and function worldwide.

 

The $650 million investment program also expands global production capabilities in additional bioprocessing manufacturing networks. Capacity expansion projects in Grand Island, N.Y., Miami, Fla., and Inchinnan, Scotland are tracking to accelerated timelines to increase production capacity for Gibco cell culture media, supplements, and process liquids as well as the manufacturing of customer-owned proprietary media formulations. Thermo Fisher's purification network, which specializes in the production of process-scale chromatography resins for a variety of applications, including vaccines and gene therapies, continues to progress in capacity expansion efforts at its POROS resin manufacturing site in Bedford, Mass. and is nearing completion of the first phase of construction at its new site in Chelmsford, Mass. 

 

For more information, please visit www.thermofisher.com/bioprocessing.

 

About Thermo Fisher Scientific

 

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.

 

 

Media contact information:

 

Ron O'Brien
781-622-1242
ron.obrien@thermofisher.com

 

Investor Contact Information:


Rafael Tejada
781-622-1356
rafael.tejada@thermofisher.com

 

 

SOURCE Thermo Fisher Scientific

 

If you have any questions regarding this Press Release, please email us at media.relations@thermofisher.com.

Thermo Fisher Scientific SUT

Sep 08, 2021

Single use technology (SUT) has become the preferred platform for development of biologics and vaccines, creating unprecedented demand in recent years. Thermo Fisher Scientific’s new SUT manufacturing facility in Nashville will more than double the company’s manufacturing capacity of SUT products including bioprocess containers and fluid transfer assemblies.

Single use technology (SUT) has become the preferred platform for development of biologics and vaccines, creating unprecedented demand in recent years. Thermo Fisher Scientific’s new SUT manufacturing facility in Nashville will more than double the company’s manufacturing capacity of SUT products including bioprocess containers and fluid transfer assemblies.

Thermo Fisher Scientific Nashville

Sep 08, 2021

Thermo Fisher Scientific is expanding its single use technology (SUT) manufacturing capabilities with a new site in Nashville. The facility will be one of the world’s largest sites of its kind and will more than double the company’s SUT manufacturing capacity to support its biopharma customers.

Thermo Fisher Scientific is expanding its single use technology (SUT) manufacturing capabilities with a new site in Nashville. The facility will be one of the world’s largest sites of its kind and will more than double the company’s SUT manufacturing capacity to support its biopharma customers.